NasdaqGS:BEAMBiotechs
A Look At Beam Therapeutics (BEAM) Valuation After Earnings Beat And Positive Clinical Updates
Beam Therapeutics earnings and clinical updates reshape investor focus
Beam Therapeutics (BEAM) stock has been in focus after first quarter results showed a net loss of US$94.32 million and a basic loss per share of US$0.91, alongside revenue that exceeded consensus estimates.
See our latest analysis for Beam Therapeutics.
The latest earnings beat on revenue and a string of encouraging clinical updates have come alongside strong recent momentum, with a 28.50% 1 month share price return and...